Zika virus (ZIKV) is a mosquito-borne virus that poses significant health risks, particularly causing serious conditions like Congenital Zika Syndrome in newborns and Guillain-Barré syndrome in adults.
The study tested a treatment called ZIKV-IG, derived from individuals who recovered from ZIKV and had strong antibodies against it, in a mouse model of ZIKV infection.
Results showed that ZIKV-IG effectively protected mice from severe ZIKV infection, reduced symptoms, and minimized tissue damage, highlighting its potential as a therapeutic option for human ZIKV infections.